STS 2021 Online: The Role of Immunotherapy in Esophageal Cancer

Immunotherapy has been used in malignancies including melanoma, renal cell carcinoma, and lung cancer. There is now an emerging role for immunotherapy in gastric and esophageal cancers. The use of immunotherapy in the setting of advanced disease has much research and some completed clinical trials. The use in neoadjuvant therapy is less well-defined, but with ongoing clinical trials, surgeons will begin to see many of these patients in their practice.

*Unless otherwise noted, speakers have nothing to disclose.

 

Moderators

Stephanie Worrell

 

Presentations:

1. Use of immunotherapy in advanced esophageal cancer - Wayne Hofstetter

2. Current clinical trials and use of immunotherapy in the neoadjuvant setting - Richard Battafarano

3. Clinical outcomes following esophagectomy after immunotherapy - Daniela Molena

4. Panel Discussion

Activity summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit
  • 0.75 Participation
Activity opens: 
03/01/2021
Activity expires: 
03/15/2024
Cost:
$0.00
Rating: 
0

Available Credit

  • 0.75 AMA PRA Category 1 Credit
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Immunotherapy has been used in malignancies including melanoma, renal cell carcinoma, and lung cancer. There is now an emerging role for immunotherapy in gastric and esophageal cancers. The use of immunotherapy in the setting of advanced disease has much research and some completed clinical trials. The use in neoadjuvant therapy is less well-defined, but with ongoing clinical trials, surgeons will begin to see many of these patients in their practice.

*Unless otherwise noted, speakers have nothing to disclose.

 

Moderators

Stephanie Worrell

 

Presentations:

1. Use of immunotherapy in advanced esophageal cancer - Wayne Hofstetter

2. Current clinical trials and use of immunotherapy in the neoadjuvant setting - Richard Battafarano

3. Clinical outcomes following esophagectomy after immunotherapy - Daniela Molena

4. Panel Discussion